NCT01174303View on ClinicalTrials.gov

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec/insulin aspart

Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.

DRUG

biphasic insulin aspart 30

Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.

Trial Locations (1)

8036

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY